Drug Shortage Report for TEVA-SPIRONOLACTONE
| Report ID | 135949 |
| Drug Identification Number | 00613223 |
| Brand name | TEVA-SPIRONOLACTONE |
| Common or Proper name | SPIRONOLACTONE 100MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | SPIRONOLACTONE |
| Strength(s) | 100MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 100 |
| ATC code | C03DA |
| ATC description | POTASSIUM-SPARING AGENTS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2021-03-17 |
| Estimated end date | 2021-05-31 |
| Actual end date | 2021-05-05 |
| Shortage status | Resolved |
| Updated date | 2021-05-06 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2021-03-18 | English | Compare |
| v2 | 2021-03-18 | French | Compare |
| v3 | 2021-04-21 | English | Compare |
| v4 | 2021-04-21 | French | Compare |
| v5 | 2021-05-06 | English | Compare |
| v6 | 2021-05-06 | French | Compare |
Showing 1 to 6 of 6